scroll to top
0

EBSCO Auth Banner

Let's find your institution. Click here.

Advanced Search Results For "NALTREXONE"

1 - 10 of 14,287 results for
 "NALTREXONE"
Results per page:

Impact of Impulsivity, Hyperactivity, and Inattention on Discontinuation Rate among Opioid-Dependent Patients Treated with Extended-Release Naltrexone.

Publication Type: Academic Journal

Source(s): International journal of environmental research and public health [Int J Environ Res Public Health] 2022 Sep 11; Vol. 19 (18). Date of Electronic Publication: 2022 Sep 11.

Abstract: Previous studies have indicated elevated levels of impulsivity, hyperactivity, and inattention (IHI) among opioid-dependent patients seeking outpatient treatment with extended-release naltrexone (XR-NTX). This led us to hypothesize that IHI may be asso...

View details

Low-dose naltrexone, an opioid-receptor antagonist, is a broad-spectrum analgesic: a retrospective cohort study.

Publication Type: Academic Journal

Source(s): Pain management [Pain Manag] 2022 Sep; Vol. 12 (6), pp. 699-709. Date of Electronic Publication: 2022 Mar 15.

Abstract: Aim: To evaluate the use of low-dose naltrexone (LDN) as a broad-spectrum analgesic. Methods: Retrospective cohort study from a single pain management practice using data from 2014 to 2020. Thirty-six patients using LDN for ≥2 months were matched to 42...

View details

Selective and antagonist-dependent µ-opioid receptor activation by the combination of 2-{[2-(6-chloro-3,4-dihydro-1(2H)-quinolinyl)-2-oxoethyl]sulfanyl}-5-phenyl-4,6-(1H,5H)-pyrimidinedione and naloxone/naltrexone.

Publication Type: Academic Journal

Source(s): Bioorganic chemistry [Bioorg Chem] 2022 Nov; Vol. 128, pp. 105905. Date of Electronic Publication: 2022 Jun 02.

Authors:

Abstract: We identified, via high-throughput screening using a FLIPR® calcium assay, compound 1, which incorporated a dihydroquinolinyl-2-oxoethylsulfanyl-(1H,5H)-pyrimidinedione core and activated the μ-opioid receptor (MOR) in the presence of naloxone or naltr...

View details

Implications of particle size on the respective solid-state properties of naltrexone in PLGA microparticles.

Publication Type: Academic Journal

Source(s): International journal of pharmaceutics [Int J Pharm] 2022 Oct 15; Vol. 626, pp. 122170. Date of Electronic Publication: 2022 Sep 05.

Abstract: A thorough understanding of the complexities in formulating and manufacturing polymeric microspheres is required for new and generic drug applications. Specifically, for an ANDA application for polymeric microsphere-based products, the applicant must m...

View details

The Effects of Menstrual Cycle Hormones on Responses to Varenicline and Naltrexone Among Female Heavy Drinking Smokers.

Publication Type: Academic Journal

Source(s): Alcohol and alcoholism (Oxford, Oxfordshire) [Alcohol Alcohol] 2022 Sep 10; Vol. 57 (5), pp. 609-614.

Abstract: Aims: Women often experience poorer smoking cessation outcomes in comparison to men. Menstrual cycle phase and sex hormones may influence smoking behavior and alter response to opioid antagonist medications. Less is known about the effects of sex hormo...

View details

Scanning Analysis of Sequential Semisolvent Vapor Impact To Study Naltrexone Release from Poly(lactide-co-glycolide) Microparticles.

Publication Type: Academic Journal

Source(s): Molecular pharmaceutics [Mol Pharm] 2022 Nov 07; Vol. 19 (11), pp. 4286-4298. Date of Electronic Publication: 2022 Sep 27.

Abstract: Poly(lactide-co-glycolide) (PLGA)-based microparticle formulations have been a mainstay of long-acting injectable drug delivery applications for decades. Despite a long history of use, tools and techniques to analyze and understand these formulations a...

View details

Effects of genotype and food on naltrexone exposure in adolescents.

Publication Type: Academic Journal

Source(s): Clinical and translational science [Clin Transl Sci] 2022 Nov; Vol. 15 (11), pp. 2732-2743. Date of Electronic Publication: 2022 Oct 05.

Abstract: Naltrexone (NTX), an opioid antagonist metabolized by aldo-keto reductase 1C4 (AKR1C4), is prescribed for psychiatric conditions like eating disorders with variable response. Systemic exposure is highly variable in adults, yet no data exist in children...

View details

Impact of Hospital-Administered Extended-Release Naltrexone on Readmission Rates in Patients With Alcohol Use Disorder: A Pilot Study.

Publication Type: Academic Journal

Source(s): The primary care companion for CNS disorders [Prim Care Companion CNS Disord] 2022 Oct 25; Vol. 24 (6). Date of Electronic Publication: 2022 Oct 25.

Abstract: Objective: To evaluate the impact of extended-release (ER) intramuscular naltrexone on readmission rates for hospitalized patients with alcohol use disorder (AUD). Methods: This was a single-center, retrospective before and...

View details

Pharmacological investigations of effort-based decision-making in humans: Naltrexone and nicotine.

Publication Type: Academic Journal

Source(s): PloS one [PLoS One] 2022 Oct 05; Vol. 17 (10), pp. e0275027. Date of Electronic Publication: 2022 Oct 05 (Print Publication: 2022).

Abstract: Many mental health disorders are characterized by an impaired ability, or willingness, to exert effort to obtain rewards. This impairment is modeled in effort-based decision tasks, and neuropharmacological studies implicate dopamine in this process. Ho...

View details

Mechanisms supporting the social regulation of neural threat responding with marital partners: A test of the opioid hypothesis.

Publication Type: Academic Journal

Source(s): Psychophysiology [Psychophysiology] 2022 Oct; Vol. 59 (10), pp. e14076. Date of Electronic Publication: 2022 Apr 19.

Abstract: Positive social contact predicts better health, but the mechanisms for this association remain debated. One way to explore this link is through the social regulation of emotion, particularly anticipatory anxiety. Previous research finds less neural thr...

View details
sponsored